Is this rising healthcare stock a good buy right now? There's a lot of excitement around Iovance Biotherapeutics (IOVA 0.87%) as its shares are up over 40% year- to-date. Investors and analysts both see even more upside for this mid-cap biotech stock in the long run. Today, however, the company remains deeply unprofitable, only recently obtaining approval from regulators for one of its treatments. Below, I'll look at what the business may look like five years from now, whether it could be profitable, and if ...